Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8
SAN DIEGO , Oct. 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind , the Company's Executive Vice President and Chief Financial Officer, will present a corporate update at the 26th Annual Credit Suisse Healthcare Conference on Wednesday, November
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7
SAN DIEGO , Oct. 30, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2017 financial results and provide a corporate update on Tuesday, November 7, 2017 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting
Significant improvement in pulmonary vascular resistance (PVR) with ralinepag compared to placebo
View HTML
Toggle Summary Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
SAN DIEGO , Sept. 6, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 29, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will participate in the following investor conferences in September: Liolios Gateway Conference - Presenting on Wednesday, September 6 at 10:00 a.m.
View HTML
Toggle Summary Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress
SAN DIEGO , Aug. 22, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results
- Achieved Positive Phase 2 Results for Ralinepag in July, Phase 3 Preparations Underway<br>- Clinical Results from Additional Phase 2 Programs Expected Over the Next Several Quarters
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017
SAN DIEGO , July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2017 financial results and provide a corporate update on Monday, August 7, 2017 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , July 31, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the underwriters of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share have exercised in full their
View HTML
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , July 12, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share.  All of the shares are being sold by Arena.  The gross proceeds
View HTML